Seeking New Digital Momentum: 2022 Annual Innovative Digital Therapeutics Cases Announced!

As Arnold said“The application of creativity and free creative activity constitute the true function of human beings.” As an emerging innovation in the healthcare sector, digital therapeutics (DTx) exemplify the industry’s exploration of creative thinking and its commitment to execution. In recent years, scenarios once confined to future visions—such as internet-based healthcare and online hospitals—have progressively become reality. Digital products are transforming our lives from multiple dimensions, while digital therapeutics have gradually entered public awareness as a novel therapeutic modality. Marking 2022 as the inaugural year of rapid development for digital therapeutics in China, numerous healthcare enterprises and institutions have accelerated their expansion into this blue-ocean market.

As a complement and optimization to traditional therapies, digital therapeutics not only provide patients with personalized and customized treatment plans but also offer healthcare professionals more opportunities for innovative practice, providing valuable data for optimizing clinical outcomes and supporting clinical research. With the growing overall health awareness in society and the increasing demand for personalized medical care, the digital therapeutics market is accelerating its development.

Digital therapeutics (DTx) products are now widely applied across multiple fields, demonstrating proven efficacy in treating conditions affecting the respiratory, nervous, and visual systems, as well as endocrine disorders, mental health conditions, circulatory system diseases, and oncology. Building on their existing medical expertise, a growing number of companies are continuously exploring and implementing practical applications, while increasing investment in the research, development, and iterative innovation of digital therapeutics products.

To better support the emergence of more high-quality enterprises and products in China’s digital therapeutics sector, help more startups find their own paths, and accelerate the profound transformation and structural evolution of healthcare service models,From November 23 to December 23, 2022, VCBeat, VB100, and Eggshell Research Institute jointly launched the Call for Innovative Case Studies in Digital Therapeutics 2022. Following evaluation by VCBeat, VB100, Eggshell Research Institute, and industry experts, the following were ultimately selected as the High-Quality Innovative Case Studies in Digital Therapeutics 2022:

Over the past two years, VCBeat has co-hostedOver 20 digital therapeutics-related events have facilitated the incubation, implementation, and promotion of digital therapeutics products across multiple provinces, cities, and enterprises, bearing witness to the evolution of China’s digital therapeutics sector from its nascent exploratory stage to one of continuous growth and breakthrough. Looking ahead, VCBeat will remain committed to closely following the digital therapeutics landscape, supporting its untapped potential for development. We are confident that in the near future, more Chinese companies and products will emerge in this field, and China’s digital therapeutics technologies will influence global healthcare, delivering improved treatment experiences to patients worldwide.